FIELD: medicine.
SUBSTANCE: invention relates to medicine and relates to the use of carnosine at a dose of 15 mg/kg as an agent for the treatment of urate nephrolithiasis.
EFFECT: invention provides an expansion of the range of agents for the treatment of urate nephrolithiasis.
1 cl, 3 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACOLOGICAL AGENT FOR THE TREATMENT OF URATE NEPHROPATHY | 2021 |
|
RU2760949C1 |
| PHARMACOLOGICAL AGENT FOR URINARY STONE DISEASE TREATMENT | 2018 |
|
RU2679120C1 |
| METHOD OF PROTEOMIC CORRECTION OF OXALATE NEPHROLITHIASIS | 2019 |
|
RU2704022C1 |
| METHOD FOR PREDICTING URATE NEPHROLITHIASIS | 2021 |
|
RU2759237C1 |
| AGENT ANTILITAL POSSESSING ANTILITOGENIC ACTION | 2012 |
|
RU2484834C1 |
| PROCESS FOR PREPARATION OF A PEPTIDE AGENT WITH ANTILITHOGENIC EFFECT | 2017 |
|
RU2652339C1 |
| AGENT STIMULATING FILTRATION AND EXCRETORY FUNCTION OF KIDNEY AT TOXIC NEPHROPATHOLOGY | 1992 |
|
RU2008912C1 |
| METHOD FOR REHABILITATION OF PATIENTS WITH RENAL DISEASE | 1999 |
|
RU2177324C2 |
| METHOD FOR THERAPY AND PREVENTION OF PROGRESSION OF CHRONIC RENAL FAILURE | 2021 |
|
RU2763661C2 |
| PEPTIDE EXHIBITING A NEPHROPROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHOD FOR APPLICATION THEREOF | 2021 |
|
RU2778505C1 |
